Emerging studies suggest Retatrutide , a dual stimulator targeting both incretin and glucose-dependent insulinotropic polypeptide , could represent retatrutide peptide a significant advancement for weight management . Initial clinical tests have shown considerable decreases in visceral mass , conceivably outperforming other body composition medicat